Eli Lilly's Q2 2026 Zepbound sales will be shaped primarily by sustained volume growth in the GLP-1 obesity segment, where the drug captured nearly 70% of new U.S. prescriptions amid expanded manufacturing capacity and international rollout. Q1 results showed Zepbound revenue at $4.16 billion, up 80% year-over-year, contributing to a company-wide beat that prompted raised full-year guidance to the $82–85 billion range. Pricing headwinds in the low- to mid-teens percent range continue to offset some gains, while competitive dynamics with Novo Nordisk's offerings and potential new oral therapies add uncertainty. Traders are focused on the August 5 earnings release for updated segment data, with market-implied odds reflecting expectations of continued momentum tempered by macroeconomic factors influencing healthcare spending.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jourNOUVEAU
5 août 2026
4 milliards $
93%
4,5 milliards de dollars
76%
5 milliards $
27%
5,5 milliards de dollars
13%
6 milliards de dollars
6%
$1,356 Vol.
4 milliards $
$160 Vol.
93%
4,5 milliards de dollars
$467 Vol.
76%
5 milliards $
$375 Vol.
27%
5,5 milliards de dollars
$140 Vol.
13%
6 milliards de dollars
$220 Vol.
6%
This market will resolve to "Yes" if Eli Lilly's Zepbound total sales for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.Eli Lilly's Q2 2026 Zepbound sales will be shaped primarily by sustained volume growth in the GLP-1 obesity segment, where the drug captured nearly 70% of new U.S. prescriptions amid expanded manufacturing capacity and international rollout. Q1 results showed Zepbound revenue at $4.16 billion, up 80% year-over-year, contributing to a company-wide beat that prompted raised full-year guidance to the $82–85 billion range. Pricing headwinds in the low- to mid-teens percent range continue to offset some gains, while competitive dynamics with Novo Nordisk's offerings and potential new oral therapies add uncertainty. Traders are focused on the August 5 earnings release for updated segment data, with market-implied odds reflecting expectations of continued momentum tempered by macroeconomic factors influencing healthcare spending.
This market will resolve to "Yes" if Eli Lilly's Zepbound total sales for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Marché ouvert : Jul 27, 2026, 1:43 PM ET
Volume
$1,356Date de fin
5 août 2026Marché ouvert
Jul 27, 2026, 1:43 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if Eli Lilly's Zepbound total sales for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.Eli Lilly's Q2 2026 Zepbound sales will be shaped primarily by sustained volume growth in the GLP-1 obesity segment, where the drug captured nearly 70% of new U.S. prescriptions amid expanded manufacturing capacity and international rollout. Q1 results showed Zepbound revenue at $4.16 billion, up 80% year-over-year, contributing to a company-wide beat that prompted raised full-year guidance to the $82–85 billion range. Pricing headwinds in the low- to mid-teens percent range continue to offset some gains, while competitive dynamics with Novo Nordisk's offerings and potential new oral therapies add uncertainty. Traders are focused on the August 5 earnings release for updated segment data, with market-implied odds reflecting expectations of continued momentum tempered by macroeconomic factors influencing healthcare spending.
This market will resolve to "Yes" if Eli Lilly's Zepbound total sales for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by September 30, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Volume
$1,356Date de fin
5 août 2026Marché ouvert
Jul 27, 2026, 1:43 PM ETResolver
0x65070BE91...Eli Lilly's Q2 2026 Zepbound sales will be shaped primarily by sustained volume growth in the GLP-1 obesity segment, where the drug captured nearly 70% of new U.S. prescriptions amid expanded manufacturing capacity and international rollout. Q1 results showed Zepbound revenue at $4.16 billion, up 80% year-over-year, contributing to a company-wide beat that prompted raised full-year guidance to the $82–85 billion range. Pricing headwinds in the low- to mid-teens percent range continue to offset some gains, while competitive dynamics with Novo Nordisk's offerings and potential new oral therapies add uncertainty. Traders are focused on the August 5 earnings release for updated segment data, with market-implied odds reflecting expectations of continued momentum tempered by macroeconomic factors influencing healthcare spending.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes